The adenosine A2A receptor is associated with methamphetamine dependence/psychosis in the Japanese population

Behavioral and Brain Functions

Volumn 6, Issue , 2010, Pages

  Kobayashi, Hideaki ^a,k   Ujike, Hiroshi ^b,j   Iwata, Nakao ^c,j   Inada, Toshiya ^d,j   Yamada, Mitsuhiko ^e,j   Sekine, Yoshimoto ^f,j   Uchimura, Naohisa ^g,j   Iyo, Masaomi ^f,j   Ozaki, Norio ^h,j   Itokawa, Masanari ⁱ   Sora, Ichiro ^a,j  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SEIWA HOSPITAL   (Japan)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^f CHIBA UNIVERSITY   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^j Japanese Genetics Initiative for Drug Abuse ^*  (Japan)

^k NIHON UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; METHAMPHETAMINE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DEPENDENCE; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTRON; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; ASIAN; DRUG ABUSE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; PSYCHOLOGICAL ASPECT; SEXUAL DEVELOPMENT;

ADULT; ALLELES; AMPHETAMINE-RELATED DISORDERS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTOR, ADENOSINE A2A; SEX CHARACTERISTICS;

EID: 77956464341     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-6-50     Document Type: Article

References (30)

1. Matsumoto T, Kamijo A, Miyakawa T, Endo K, Yabana T, Kishimoto H, Okudaira K, Iseki E, Sakai T, Kosaka K. Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration. Addiction 2002, 97:809-817. 10.1046/j.1360-0443.2002.00143.x, 12133119.
2. Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Subst Abus 2008, 29:31-49. 10.1080/08897070802218554, 2597382, 19042205.
3. Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Sora I, Iyo M, Katsu T, Nomura A, Nakata K, Ozaki N. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 2003, 3:242-247. 10.1038/sj.tpj.6500189, 12931138.
4. Sato M, Chen CC, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983, 18:429-440.
5. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001, 158:377-382. 10.1176/appi.ajp.158.3.377, 11229977.
6. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996, 2:699-703. 10.1038/nm0696-699, 8640565.
7. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988, 85:5274-5278. 10.1073/pnas.85.14.5274, 281732, 2899326.
8. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612. 10.1038/379606a0, 8628395.
9. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997, 20:482-487. 10.1016/S0166-2236(97)01096-5, 9347617.
10. Ferre S, Fuxe K, von Euler G, Johansson B, Fredholm BB. Adenosine-dopamine interactions in the brain. Neuroscience 1992, 51:501-512. 10.1016/0306-4522(92)90291-9, 1488111.
11. Poleszak E, Malec D. Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity. Pol J Pharmacol 2002, 54:359-366.
12. Munzar P, Justinova Z, Kutkat SW, Ferre S, Goldberg SR. Adenosinergic modulation of the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology (Berl) 2002, 161:348-355. 10.1007/s00213-002-1075-5, 12073161.
13. Poleszak E, Malec D. Influence of adenosine receptor agonists and antagonists on amphetamine-induced stereotypy in rats. Pol J Pharmacol 2000, 52:423-429.
14. Chen JF, Beilstein M, Xu YH, Turner TJ, Moratalla R, Standaert DG, Aloyo VJ, Fink JS, Schwarzschild MA. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 2000, 97:195-204. 10.1016/S0306-4522(99)00604-1, 10771351.
15. Chen JF, Moratalla R, Yu L, Martin AB, Xu K, Bastia E, Hackett E, Alberti I, Schwarzschild MA. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology 2003, 28:1086-1095.
16. Ujike H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep 2002, 4:177-184. 10.1007/s11920-002-0024-7, 12003679.
17. Schneider S, Roessli D, Excoffier L. Arlequin: a software for population genetics data analysis. Ver 2.000. Genetics and Biometry Lab, Department of Anthropology, University of Geneva 2000,
18. Yamada K, Hattori E, Shimizu M, Sugaya A, Shibuya H, Yoshikawa T. Association studies of the cholecystokinin B receptor and A2a adenosine receptor genes in panic disorder. J Neural Transm 2001, 108:837-848. 10.1007/s007020170033, 11515749.
19. Alsene K, Deckert J, Sand P, de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003, 28:1694-1702. 10.1038/sj.npp.1300232, 12825092.
20. Heffner TG, Wiley JN, Williams AE, Bruns RF, Coughenour LL, Downs DA. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology (Berl) 1989, 98:31-37. 10.1007/BF00442002, 2498959.
21. Popoli P, Pezzola A, de Carolis AS. Modulation of striatal adenosine A1 and A2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. Eur J Pharmacol 1994, 257:21-25. 10.1016/0014-2999(94)90689-0, 8082703.
22. Shimazoe T, Yoshimatsu A, Kawashimo A, Watanabe S. Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization. Eur J Pharmacol 2000, 388:249-254. 10.1016/S0014-2999(99)00899-7, 10675733.
23. Knapp CM, Foye MM, Cottam N, Ciraulo DA, Kornetsky C. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol Biochem Behav 2001, 68:797-803. 10.1016/S0091-3057(01)00486-5, 11526979.
24. Hohoff C, McDonald JM, Baune BT, Cook EH, Deckert J, de Wit H. Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. Am J Med Genet B Neuropsychiatr Genet 2005, 139B:42-44. 10.1002/ajmg.b.30228, 16118787.
25. Sery O, Vojtova V, Zvolsky P. The association study of DRD2, ACE and AGT gene polymorphisms and metamphetamine dependence. Physiol Res 2001, 50:43-50.
26. Lin SK, Chen CK, Ball D, Liu HC, Loh EW. Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder. Pharmacogenomics J 2003, 3:349-355. 10.1038/sj.tpj.6500203, 14569258.
27. Kobayashi H, Ide S, Hasegawa J, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Shen HW, Ikeda K, Sora I. Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann N Y Acad Sci 2004, 1025:325-334. 10.1196/annals.1316.040, 15542733.
28. Koizumi H, Hashimoto K, Kumakiri C, Shimizu E, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Takei N, Iyo M. Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers. Am J Med Genet B Neuropsychiatr Genet 2004, 126B:43-45. 10.1002/ajmg.b.20148, 15048646.
29. Dluzen DE, Liu B. Gender differences in methamphetamine use and responses: a review. Gend Med 2008, 5:24-35. 10.1016/S1550-8579(08)80005-8, 18420163.
30. Deckert J, Nothen MM, Rietschel M, Wildenauer D, Bondy B, Ertl MA, Knapp M, Schofield PR, Albus M, Maier W, Propping P. Human adenosine A2a receptor (A2aAR) gene: systematic mutation screening in patients with schizophrenia. J Neural Transm 1996, 103:1447-1455. 10.1007/BF01271259, 9029412.